XRCC3 gene polymorphism is associated with survival in Japanese lung cancer patients

International Journal of Molecular Sciences

Volumn 13, Issue 12, 2012, Pages 16658-16667

  Osawa, Kayo ^a   Nakarai, Chiaki ^a   Uchino, Kazuya ^b   Yoshimura, Masahiro ^b   Tsubota, Noriaki ^c   Takahashi, Juro ^a   Kido, Yoshiaki ^a,d  

^a KOBE UNIVERSITY   (Japan)

^b HYOGO CANCER CENTER   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA repair; Gene polymorphisms; Lung cancer; Survival; XRCC3

Indexed keywords

8 OXOGUANINE DNA GLYCOSYLASE; ARGININE; ASPARTIC ACID; CYSTEINE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA GLYCOSYLASE MUTY; DNA GLYCOSYLTRANSFERASE; GLUTAMIC ACID; GLUTAMINE; HISTIDINE; METHIONINE; SERINE; THREONINE; UNCLASSIFIED DRUG; XRCC1 PROTEIN; XRCC3 PROTEIN; DNA BINDING PROTEIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 3;

ADULT; AGED; APEX1 GENE; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONFIDENCE INTERVAL; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAZARD RATIO; HUMAN; JAPANESE; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTYH GENE; OGG1 GENE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; SURVIVAL TIME; XRCC1 GENE; XRCC3 GENE; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FOLLOW UP; GENETICS; JAPAN; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; RISK FACTOR; SURVIVAL RATE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; SURVIVAL RATE;

EID: 84871707535     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131216658     Document Type: Article

References (25)

1. Pisani, P.; Parkin, D.M.; Ferlay, J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer 1993, 55, 891-903.
2. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74108.
3. Yu, Z.; Chen, J.; Ford, B.N.; Brackley, M.E.; Glickman, B.W. Human DNA repair systems: An overview. Environ. Mol. Mutagen. 1999, 33, 3-20.
4. Wood, R.D.; Mitchell, M.; Sgouros, J.; Lindahl, T. Human DNA repair genes. Science 2001, 291, 1284-1289.
5. Le Marchand, L.; Donlon, T.; Lum-Jones, A.; Seifried, A.; Wilkens, L.R. Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. Cancer Epidemiol. Biomark. Prev. 2002, 11, 409-412.
6. Kasahara, M.; Osawa, K.; Yoshida, K.; Miyaishi, A.; Osawa, Y.; Inoue, N.; Tsutou, A.; Tabuchi, Y.; Tanaka, K.; Yamamoto, M.; et al. Association of MUTYH Gln324His and APEX1 Asp148Glu with colorectal cancer and smoking in a Japanese population. J. Exp. Clin. Cancer Res. 2008, 27, 49.
7. Miyaishi, A.; Osawa, K.; Osawa, Y.; Inoue, N.; Yoshida, K.; Kasahara, M.; Tsutou, A.; Tabuchi, Y.; Sakamoto, K.; Tsubota, N.; et al. MUTYH Gln324His gene polymorphism and genetic susceptibility for lung cancer in a Japanese population. J. Exp. Clin. Cancer Res. 2009, 28, 10.
8. Bennett, R.A.; Wilson, D.M., III; Wong, D.; Demple, B. Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway. Proc. Natl. Acad. Sci. USA 1997, 94, 7166-7169.
9. Osawa, K.; Miyaishi, A.; Uchino, K.; Osawa, Y.; Inoue, N.; Nakarai, C.; Tsutou, A.; Kido, Y.; Yoshimura, M.; Tsubota, N.; et al. APEX1 Asp148Glu gene polymorphism is a risk factor for lung cancer in relation to smoking in Japanese. Asian Pac. J. Cancer Prev. 2010, 11, 1181-1186.
10. Matullo, G.; Palli, D.; Peluso, M.; Guarrera, S.; Carturan, S.; Celentano, E.; Krogh, V.; Munnia, A.; Tumino, R.; Polidoro, S.; et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001, 22, 1437-1445.
11. Gurubhagavatula, S.; Liu, G.; Park, S.; Zhou, W.; Su, L.; Wain, J.C.; Lynch, T.J.; Neuberg, D.S.; Christiani, D.C. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 2004, 22, 2594-2601.
12. Ryu, J.S.; Hong, Y.C.; Han, H.S.; Lee, J.E.; Kim, S.; Park, Y.M.; Kim, Y.C.; Hwang, T.S. Association between polymorphisms of ERCC1 and XPD and survival in non-small-celllung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44, 311-316.
13. Wei, Q.; Spitz, M.R. The role of DNA repair capacity in susceptibility to lung cancer: A review. Cancer Metastasis Rev. 1997, 16, 295-307.
14. Osawa, K. SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients. Pharmacogenomics 2011, 12, 445-447.
15. Osawa, K. Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi 2009, 12, 837-840.
16. Takenaka, T.; Yano, T.; Kiyohara, C.; Miura, N.; Kouso, H.; Ohba, T.; Kometani, T.; Shoji, F.; Yoshino, I.; Maehara, Y. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010, 67, 101-107.
17. Wu, X.; Shell, S.M.; Yang, Z.; Zou, Y. Phosphorylation of nucleotide excision repair factor xeroderma pigmentosum group A by ataxia telangiectasia mutated and Rad3-related-dependent checkpoint pathway promotes cell survival in response to UV irradiation. Cancer Res. 2006, 66, 2997-3005.
18. Sreeja, L.; Syamala, V.S.; Syamala, V.; Hariharan, S.; Raveendran, P.B.; Vijayalekshmi, R.V.; Madhavan, J.; Ankathil, R. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J. Cancer Res. Clin. Oncol. 2008, 134, 645-652.
19. Hsieh, W.C.; Cheng, Y.W.; Lin, C.J.; Chou, M.C.; Chen, C.Y.; Lee, H. Prognostic significance of X-ray cross-complementing group 1 T-77C polymorphism in resected non-small cell lung cancer. Jpn. J. Clin. Oncol. 2009, 39, 81-85.
20. Liao, W.Y.; Shih, J.Y.; Chang, G.C.; Cheng, Y.K.; Yang, J.C.; Chen, Y.M.; Yu, C.J. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J. Thorac. Oncol. 2012, 7, 973-981.
21. Yin, Z.; Zhou, B.; He, Q.; Li, M.; Guan, P.; Li, X.; Cui, Z.; Xue, X.; Su, M.; Ma, R.; et al. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer 2009, 9, 439.
22. De las Peñas, R.; Sanchez-Ronco, M.; Alberola, V.; Taron, M.; Camps, C.; Garcia-Carbonero, R.; Massuti, B.; Queralt, C.; Botia, M.; Garcia-Gomez, R.; et al. Spanish Lung Cancer Group. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann. Oncol. 2006, 17, 668-675.
23. Butkiewicz, D.; Rusin, M.; Sikora, B.; Lach, A.; Chora{ogonek}ży, M. An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer. Mol. Biol. Rep. 2011, 38, 5231-5241.
24. Ahrendt, S.A.; Hu, Y.; Buta, M.; McDermott, M.P.; Benoit, N.; Yang, S.C.; Wu, L.; Sidransky, D. p53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study. J. Natl. Cancer Inst. 2003, 95, 961-970.
25. Osawa, Y.; Osawa, K.; Miyaishi, A.; Higuchi, M.; Tsutou, A.; Matsumura, S.; Tabuchi, Y.; Tsubota, N.; Takahashi, J. NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac. J. Cancer Prev. 2007, 8, 103-108.